SARS-CoV-2 associated pathogenesis, immune dysfunction and involvement of host factors: a comprehensive review
暂无分享,去创建一个
Y. Waheed | Khan Muhammad | H. Hetta | M. Imran | A. Al-Shehhi | Z. Jamil | W. Waqar | S. Ismail
[1] Y. Waheed,et al. Mapping the effect of drugs on ACE2 as a novel target site for COVID-19 therapy. , 2021, European review for medical and pharmacological sciences.
[2] Sara Zandpazandi,et al. Novel Coronavirus Characteristic Cerebrovasculopathic Effects , 2020, International Clinical Neuroscience Journal.
[3] C. Wellington,et al. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome , 2020, European Respiratory Journal.
[4] Xiaodong Sun,et al. Attaching clinical significance to COVID-19-associated diarrhea , 2020, Life Sciences.
[5] B. Reinius,et al. Natural killer cell immunotypes related to COVID-19 disease severity , 2020, Science Immunology.
[6] N. Sultana,et al. Multisystem inflammatory syndrome associated with COVID-19 in children in Pakistan , 2020, The Lancet Child & Adolescent Health.
[7] K. Seino,et al. Macrophage activation syndrome and COVID-19 , 2020, Inflammation and regeneration.
[8] G. Batiha,et al. Investigating Virological, Immunological, and Pathological Avenues to Identify Potential Targets for Developing COVID-19 Treatment and Prevention Strategies , 2020, Vaccines.
[9] I. Artika,et al. Molecular biology of coronaviruses: current knowledge , 2020, Heliyon.
[10] P. Brindley,et al. Therapeutic plasma exchange in adult critically ill patients with life-threatening SARS-CoV-2 disease: A pilot study , 2020, Journal of Critical Care.
[11] Chunrui Li,et al. Risk factors for developing into critical COVID-19 patients in Wuhan, China: A multicenter, retrospective, cohort study , 2020, EClinicalMedicine.
[12] Z. Memish,et al. Lung Injury in COVID-19—An Emerging Hypothesis , 2020, ACS chemical neuroscience.
[13] A. Thierry. Host/genetic factors associated with COVID-19 call for precision medicine , 2020, Precision clinical medicine.
[14] M. Chung,et al. New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis , 2020, BMC Medicine.
[15] P. Davies,et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study , 2020, The Lancet Child & Adolescent Health.
[16] D. Gladstone,et al. Regulatory T Cells for Treating Patients With COVID-19 and Acute Respiratory Distress Syndrome: Two Case Reports , 2020, Annals of Internal Medicine.
[17] B. Pitard,et al. Potential of regulatory T-cell-based therapies in the management of severe COVID-19 , 2020, European Respiratory Journal.
[18] K. Muhammad,et al. Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19 , 2020, Nanomedicine.
[19] M. Usman,et al. COVID-19 and Liver Injury: A Systematic Review and Meta-Analysis , 2020, Cureus.
[20] T. Mogensen,et al. Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19 , 2020, Frontiers in Immunology.
[21] Simon Li,et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents , 2020, The New England journal of medicine.
[22] C. von Kalle,et al. COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis , 2020, Nature Biotechnology.
[23] R. Auer,et al. Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies , 2020, Frontiers in Immunology.
[24] N. E. Ferreira,et al. First case of SARS-COV-2 sequencing in cerebrospinal fluid of a patient with suspected demyelinating disease , 2020, Journal of Neurology.
[25] R. Ranjbar,et al. An updated review of the association of host genetic factors with susceptibility and resistance to COVID‐19 , 2020, Journal of cellular physiology.
[26] Yuan Wang,et al. Identifying airborne transmission as the dominant route for the spread of COVID-19 , 2020, Proceedings of the National Academy of Sciences.
[27] S. Vanni,et al. Interleukin-6 as prognosticator in patients with COVID-19 , 2020, Journal of Infection.
[28] Jérémie F. Cohen,et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study , 2020, BMJ.
[29] R. Sagkan,et al. Structural variations and expression profiles of the SARS‐CoV‐2 host invasion genes in lung cancer , 2020, Journal of medical virology.
[30] Shelly L. Miller,et al. How can airborne transmission of COVID-19 indoors be minimised? , 2020, Environment International.
[31] M. Ono,et al. T-Cell Hyperactivation and Paralysis in Severe COVID-19 Infection Revealed by Single-Cell Analysis , 2020, bioRxiv.
[32] L. León,et al. Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents , 2020, medRxiv.
[33] M. Bosmann. Complement Activation during Critical Illness: Current Findings and an Outlook in the Era of COVID-19 , 2020, American journal of respiratory and critical care medicine.
[34] W. Wang,et al. Viral and host factors related to the clinical outcome of COVID-19 , 2020, Nature.
[35] Cong Ye,et al. The immunology of COVID-19: is immune modulation an option for treatment? , 2020, The Lancet Rheumatology.
[36] N. Henninger,et al. SARS2-CoV-2 and Stroke in a New York Healthcare System , 2020, Stroke.
[37] B. Lipworth,et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19 , 2020, Journal of Allergy and Clinical Immunology.
[38] L. Bonnemains,et al. Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic , 2020, Circulation.
[39] D. Bennett,et al. COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs , 2020, Annals of the Rheumatic Diseases.
[40] Giuseppe Magro,et al. SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the ‘culprit lesion’ of ARDS onset? What is there besides Tocilizumab? SGP130Fc , 2020, Cytokine: X.
[41] Angelo Mazza,et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study , 2020, The Lancet.
[42] I. Amit,et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 , 2020, Nature Medicine.
[43] C. D. Dela Cruz,et al. COVID-19 vulnerability: the potential impact of genetic susceptibility and airborne transmission , 2020, Human Genomics.
[44] Jian Chen,et al. Association between ABO blood groups and risk of SARS‐CoV‐2 pneumonia , 2020, British journal of haematology.
[45] A. Julià,et al. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs , 2020, Seminars in Arthritis and Rheumatism.
[46] Marco Maria Fontanella,et al. SARS-CoV-2 can induce brain and spine demyelinating lesions , 2020, Acta Neurochirurgica.
[47] G. Cooke,et al. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[48] Kwok-Hung Chan,et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial , 2020, The Lancet.
[49] J. Rose,et al. SARS-CoV-2 in wastewater: State of the knowledge and research needs , 2020, Science of The Total Environment.
[50] J. Knight,et al. Interferon-Induced Transmembrane Protein 3 Genetic Variant rs12252-C Associated With Disease Severity in Coronavirus Disease 2019 , 2020, The Journal of infectious diseases.
[51] Xiaohu Zheng,et al. Effective treatment of severe COVID-19 patients with tocilizumab , 2020, Proceedings of the National Academy of Sciences.
[52] X. Tang,et al. Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.
[53] J. Sejvar,et al. Neurological associations of COVID-19 , 2020, The Lancet Neurology.
[54] H. Hou,et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. , 2020, JCI insight.
[55] Ahmed Yaqinuddin,et al. Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents , 2020, Medical Hypotheses.
[56] T. Zhang,et al. COVID-19-Associated Acute Disseminated Encephalomyelitis: A Case Report , 2020, medRxiv.
[57] J. Sheng,et al. Current epidemiological and clinical features of COVID-19; a global perspective from China , 2020, Journal of Infection.
[58] Dong Men,et al. Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease 2019 , 2020, Clinical Infectious Diseases.
[59] Abhinav Nellore,et al. Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome Coronavirus 2 , 2020, Journal of Virology.
[60] Nathaniel Hupert,et al. Clinical Characteristics of Covid-19 in New York City , 2020, The New England journal of medicine.
[61] M. Woodward,et al. The impact of 2019 novel coronavirus on heart injury: A Systematic review and Meta-analysis , 2020, Progress in Cardiovascular Diseases.
[62] S. Kremer,et al. Neurologic Features in Severe SARS-CoV-2 Infection , 2020, The New England journal of medicine.
[63] A. Carr. A new clinical trial to test high-dose vitamin C in patients with COVID-19 , 2020, Critical Care.
[64] S. Merler,et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. , 2020, JAMA.
[65] Roland Eils,et al. SARS‐CoV‐2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells , 2020, The EMBO journal.
[66] D. McGonagle,et al. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease , 2020, Autoimmunity Reviews.
[67] Huji Xu,et al. Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process , 2020, Gut.
[68] Dingding Shen,et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? , 2020, The Lancet Neurology.
[69] Roberto Maroldi,et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). , 2020, JAMA cardiology.
[70] Ke Ma,et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study , 2020, BMJ.
[71] Han Zhang,et al. Coronavirus Disease 2019 (COVID-19) CT Findings: A Systematic Review and Meta-analysis , 2020, Journal of the American College of Radiology.
[72] M. D. De Buyzere,et al. The host’s angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections , 2020, Clinica Chimica Acta.
[73] F. Diekmann,et al. Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation? , 2020, American Journal of Transplantation.
[74] Z. Tian,et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients , 2020, Cellular & Molecular Immunology.
[75] Fenglian Ma,et al. Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin , 2020, European heart journal.
[76] Hyeshik Chang,et al. The Architecture of SARS-CoV-2 Transcriptome , 2020, Cell.
[77] Jie Hao,et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection , 2020, Frontiers of Medicine.
[78] G. Herrler,et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.
[79] M. Torcia,et al. Evidence for host-dependent RNA editing in the transcriptome of SARS-CoV-2 , 2020, bioRxiv.
[80] P. Mehta,et al. COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.
[81] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[82] Ting Yu,et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.
[83] Lei Zhao,et al. Multiple Enzyme Release, Inflammation Storm and Hypercoagulability Are Prominent Indicators For Disease Progression In COVID-19: A Multi-Centered, Correlation Study with CT Imaging Score , 2020 .
[84] C. Akdis,et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China , 2020, Allergy.
[85] Jiyuan Zhang,et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.
[86] Lijuan Xiong,et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients , 2020, EBioMedicine.
[87] Suxin Wan,et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP) , 2020, medRxiv.
[88] Jue Fan,et al. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection , 2020, bioRxiv.
[89] E. Holmes,et al. A new coronavirus associated with human respiratory disease in China , 2020, Nature.
[90] S. Lindstrom,et al. First Case of 2019 Novel Coronavirus in the United States , 2020, The New England journal of medicine.
[91] I. Kickbusch,et al. Response to the emerging novel coronavirus outbreak , 2020, BMJ.
[92] E. Holmes,et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.
[93] Ting Yu,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.
[94] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[95] Qianyun Liu,et al. Emerging coronaviruses: Genome structure, replication, and pathogenesis , 2020, Journal of medical virology.
[96] Ping Chen,et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission , 2020, Science China Life Sciences.
[97] R. Tattersall,et al. Haemophagocytic lymphohisticytosis—an underrecognized hyperinflammatory syndrome , 2019, Rheumatology.
[98] N. Gupta,et al. The stimulation of thrombosis by hypoxia. , 2019, Thrombosis research.
[99] H. Ljunggren,et al. NK cells are activated and primed for skin-homing during acute dengue virus infection in humans , 2019, Nature Communications.
[100] Yi Fan,et al. Bat Coronaviruses in China , 2019, Viruses.
[101] S. Sakaguchi,et al. Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer. , 2019, Immunity.
[102] K. Nichols,et al. The Immunology of Macrophage Activation Syndrome , 2019, Front. Immunol..
[103] G. Lombardi,et al. Past, Present, and Future of Regulatory T Cell Therapy in Transplantation and Autoimmunity , 2019, Front. Immunol..
[104] R. Fouchier,et al. Transmission routes of respiratory viruses among humans , 2018, Current Opinion in Virology.
[105] H. Ljunggren,et al. NK Cell Responses to Human Tick-Borne Encephalitis Virus Infection , 2016, The Journal of Immunology.
[106] D. Falzarano,et al. SARS and MERS: recent insights into emerging coronaviruses , 2016, Nature Reviews Microbiology.
[107] David K. Meyerholz,et al. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice , 2016, Cell Host & Microbe.
[108] B. Miller,et al. Hypoxia mediated pulmonary edema: potential influence of oxidative stress, sympathetic activation and cerebral blood flow , 2015, BMC Physiology.
[109] A. Rudensky,et al. A Distinct Function of Regulatory T Cells in Tissue Protection , 2015, Cell.
[110] Q. Ying,et al. Formation of urban fine particulate matter. , 2015, Chemical reviews.
[111] S. Weiss,et al. Coronavirus Pathogenesis , 2011, Advances in Virus Research.
[112] H. Ljunggren,et al. Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus , 2011, The Journal of experimental medicine.
[113] P. Sham,et al. Significance of the Myxovirus Resistance A (MxA) Gene — 123C>A Single-Nucleotide Polymorphism in Suppressed Interferon β Induction of Severe Acute Respiratory Syndrome Coronavirus Infection , 2010, The Journal of infectious diseases.
[114] Eric Vivier,et al. Functions of natural killer cells , 2008, Nature Immunology.
[115] Fang Li,et al. Structural Analysis of Major Species Barriers between Humans and Palm Civets for Severe Acute Respiratory Syndrome Coronavirus Infections , 2008, Journal of Virology.
[116] J. Habbema,et al. Association of SARS susceptibility with single nucleic acid polymorphisms of OAS1 and MxA genes: a case-control study , 2006, BMC infectious diseases.
[117] John L. Sullivan,et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.
[118] J. Luban. SARS-CoV-2 , 2020 .
[119] V. Georgiev,et al. National Institute of Allergy and Infectious Diseases, NI , 2008 .